结节病的研究进展

方一兵

doi:10.19837/j.cnki.ahyf.2021.02.008

PDF(841 KB)

安徽预防医学杂志 ›› 2021, Vol. 27 ›› Issue (2) : 116-119. DOI: 10.19837/j.cnki.ahyf.2021.02.008

综述

结节病的研究进展

方一兵

作者信息 +

Research progress of sarcoidosis

FANG Yi-bing

Author information +

文章历史 +

摘要

结节病是一种原因不明的肉芽肿性疾病,通常累及肺部,临床表现多种多样、预后差异极大。确诊依赖于组织学中发现非干酪性肉芽肿,支气管镜检查是获取病理组织的最常用方法。肺纤维化、肺功能受损和肺动脉高压是临床预后不良的危险因素。糖皮质激素是最常用的一线治疗,免疫抑制剂通常作为糖皮质激素的替代方案,TNFα拮抗剂通常用于难治性结节病患者。

Abstract

Sarcoidosis is a granulomatous disease of unknown cause,usually involving the lungs,with various clinical manifestations and extremely variable prognosis.The diagnosis depends on the finding of non caseous granuloma in histology,and bronchoscopy is the most common method to obtain pathological tissue.Pulmonary fibrosis,impaired pulmonary function and pulmonary hypertension are risk factors for poor prognosis.Glucocorticoid is the most commonly used first-line treatment,immunosuppressants are usually used as an alternative to glucocorticoid,and TNFα antagonists are usually used in patients with refractory sarcoidosis.

导出引用

方一兵. 结节病的研究进展[J]. 安徽预防医学杂志. 2021, 27(2): 116-119 https://doi.org/10.19837/j.cnki.ahyf.2021.02.008

FANG Yi-bing. Research progress of sarcoidosis[J]. Anhui Journal of Preventive Medicine. 2021, 27(2): 116-119 https://doi.org/10.19837/j.cnki.ahyf.2021.02.008

中图分类号： R563

参考文献

[1] Cozier YC.Assessing the worldwide epidemiology of sarcoidosis: challenges and future directions[J].Eur Respir J,2016,48(6): 1545-1548.
[2] Grunewald J,Spagnolo P,Wahlstrom J,et al.Immunogenetics of disease-causing inflammation in sarcoidosis[J].Clin Rev Allergy Immunol,2015,49(1): 19-35.
[3] Gerke AK,Judson MA,Cozier YC,et al.Disease burden and variability in sarcoidosis[J].Ann Am Thorac Soc,2017,14(Supplement_6): S421-S428.
[4] Kirkil G,Lower EE,Baughman RP.Predictors of mortality in pulmonary sarcoidosis[J].Chest,2018,153(1): 105-113.
[5] Walsh SL,Wells AU,Sverzellati N,et al.An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study[J].Lancet Respir Med,2014,2(2): 123-130.
[6] Khan NA,Donatelli CV,Tonelli AR,et al.Toxicity risk from glucocorticoids in sarcoidosis patients[J].Respir Med,2017,132(11): 9-14.
[7] Spagnolo P.Sarcoidosis: a critical review of history and milestones[J]. Clinic Rev Allerg Immunol,2015,49(1): 1-5.
[8] Arkema EV,Grunewald J,Kullberg S,et al.Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden[J].Eur Respir J,2016,48(6): 1690-1699.
[9] Baughman RP,Field S,Costabel U,et al.Sarcoidosis in America.Analysis based on health care use[J].Ann Am Thorac Soc,2016,13(8): 1244-1252.
[10] Duchemann B,Annesi-Maesano I,Jacobe de Naurois C,et al.Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris[J].Eur Respir J,2017,50(2): 1602419.
[11] Mirsaeidi M,Machado RF,Schraufnagel D,et al.Racial difference in sarcoidosis mortality in the United States[J].Chest,2015,147(2): 438-449.
[12] Jamilloux Y,Maucort-Boulch D,Kerever S,et al.Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis[J].Eur Respir J,2016,48(6): 1700-1709.
[13] Ungprasert P,Carmona EM,Utz JP,et al.Epidemiology of sarcoidosis 1946-2013: a population-based study[J].Mayo Clin Proc,2016,91(2): 183-188.
[14] Rossi G,Cavazza A,Colby TV.Pathology of sarcoidosis[J].Clin Rev Allergy Immunol,2015,49(1): 36-44.
[15] Aleksonieniūnas M,et al.Relationship between radiologic patterns,pulmonary function values and bronchoalveolar lavage fluid cells in newly diagnosed sarcoidosis[J].J Thorac Dis, 2017,9(1):88-95.
[16] Calandriello L,Walsh SLF.Imaging for sarcoidosis[J].Semin Respir Crit Care Med,2017,38(4): 417-436.
[17] Cozzi D,Bargagli E,Calabrò AG,et al.Atypical HRCT manifestations of pulmonary sarcoidosis[J].Radiol Med,2018,123(8):174-184.
[18] Valeyre D,Prasse A,Nunes H,et al.Sarcoidosis[J].Lancet,2014,383(9923): 1155-1167.
[19] Dziedzic DA.,Peryt A,Orlowski T.The role of EBUS-TBNA and standard bronchoscopic modalities in the diagnosis of sarcoidosis[J].Clin Respir J,2017,11(1):58-63.
[20] 陈小波,罗群,陈愉,等.冷冻肺活检对间质性肺疾病诊断有效性及安全性的前瞻性研究[J].中华结核和呼吸杂志,2018,41(6):467-671.
[21] Aragaki-Nagahodo AA,Baughman RP,Shipley RT,et al.The complimentary role of transbronchial lung cryobiopsy and endobronchial ultrasound fine needle aspiration in the diagnosis of sarcoidosis[J].Respir Med,2017,131(10): 65-69.
[22] Zappala CJ,Desai SR,Copley SJ,et al.Accuracy of individual variables in the monitoring of long-term change in pulmonary sarcoidosis as judged by serial high-resolution CT scan data[J]. Chest,2014,145(1): 101-107.
[23] Baughman RP,Grutters JC.New treatment strategies for pulmonary sarcoidosis: antimetabolites,biological drugs,and other treatment approaches[J].Lancet Respir Med,2015,3(10): 813-822.
[24] Goljan-Geremek A,Bednarek M,Franczuk M,et al.Methotrexate as a single agent for treating pulmonary sarcoidosis: a single centre real-life prospective study[J].Pneumonol Alergol Pol,2014,82(6):518-533.
[25] James WE.,Baughman R.Treatment of Sarcoidosis: grading the evidence[J].Expert Rev Clin Pharmacol, 2018,11(7):677-687.
[26] Jamilloux Y,Cohenaubart F,Chapelonabric C,et al.Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients.[J].Semin Arthritis Rheum,2017,47(2):288-294.
[27] Vorselaars AD,Crommelin HA,Deneer VH,et al.Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis[J].Eur Respir J, 2015,46(1): 175-185.
[28] Crommelin HA,van der Burg LM,Vorselaars AD,et al.Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab[J].Respir Med,2016,115(6):72-77.
[29] Hong A,King CS,Brown AW,et al.Hemothorax following lung transplantation: incidence,risk factors,and effect on morbidity and mortality[J].Multidiscip Respir Med,2016,11(1):40.
[30] Taimeh Z,Hertz MI,Shumway S,et al.Lung transplantation for pulmonary sarcoidosis.Twenty-five years of experience in the USA[J].Thorax,2016,71(4): 378-79.